Provectus’s Substack
Provectus BiopharmaceuticalsA clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of synthetic small molecule halogenated xanthenes, with lead molecule rose bengal sodium.
| Platform |  | Pricing | Only free issues | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 34 | Subscribers | Read | provectus.substack.com |
Curious about how many subscribers Provectus’s Substack has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over one million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Provectus News Day: July 4, 2024
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) uses GlobeNewswire-distributed press releases, U.S. Securities and Exchange Commission (SEC) filings, and its website to disclose material financial and operational information to shareholder...
Provectus Announces Investor Webinar of 2024 Annual Meeting for June 20th at 4 pm ET
On Thursday, Provectus announced that its 2024 annual stockholder meeting (2024 Annual Meeting) will be accessible by Zoom Webinar. The meeting will be held on Thursday, June 20, 2024 at the Hilton Knoxville, located at 501 West Church Aven...
News Day: May 17, 2024
#### New Provectus investor presentation
Intralesional Path to Cancer Drug Approval
Multiple investigational intralesional (IL) agents have been tested across a range of solid tumor cancer types, in addition to synthetic small molecule PV-10. While the majority of these IL agents have been oncolytic viruses (OVs), several ...
Authors
The writers behind this newsletter.
We are a clinical-stage biotech developing immunotherapy medicines for different diseases based on a class of small molecules called halogenated xanthenes.
Frequently Asked Questions
How can I access the email archive for Provectus’s Substack?
You can find recent issues that have been published by Provectus’s Substack on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Provectus’s Substack have?
To see how many people subscribe to Provectus’s Substack, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Provectus’s Substack?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Provectus’s Substack as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Provectus’s Substack?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Provectus’s Substack using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to Provectus’s Substack?
Scroll up to where it says Similar Newsletters to see other publications like Provectus’s Substack. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Provectus’s Substack?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.